ReviewMolecules (Basel, Switzerland)2018
Isoxazole Derivatives as Regulators of Immune Functions.
Review in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 97 citations in OpenAlex.
- Article
- Hybrid Isoxazole-Hydroxyapatite composites as antimicrobial agents: integrated in silico and in vitro investigation.Journal of materials science. Materials in medicine · 2026Article
- New isoxazole-based heterocyclic hybrids with dual antimicrobial and antioxidant bioactivity: integrated synthesis,RSC advances · 2026Article
- Regioselective approach to 5-arylsulfonylisoxazoles and their antimicrobial activity.Beilstein journal of organic chemistry · 2026Article
- N2 modified cap analogues as translation inhibitors and substrates for preparation of therapeutic mRNA.European biophysics journal : EBJ · 2023Review
- Design and Development of COX-II Inhibitors: Current Scenario and Future Perspective.ACS omega · 2023Review
- Nitrile Oxide, Alkenes, Dipolar Cycloaddition, Isomerization and Metathesis Involved in the Syntheses of 2-Isoxazolines.Molecules (Basel, Switzerland) · 2023Review
- Synthesis of novel sulphamethoxazole derivatives and exploration of their anticancer and antimicrobial properties.PloS one · 2023Article
- Synthesis,Frontiers in chemistry · 2023Article
- 5-Amino-3-methyl-Isoxazole-4-carboxylic Acid as a Novel Unnatural Amino Acid in the Solid Phase Synthesis of α/β-Mixed Peptides.Molecules (Basel, Switzerland) · 2022Article
- Isoxazole Derivatives against Carbonic Anhydrase: Synthesis, Molecular Docking, MD Simulations, and Free Energy Calculations Coupled withACS omega · 2022Article
- Degrading Characterization of the Newly IsolatedMicroorganisms · 2022Article
- Poly ε-Caprolactone Nanoparticles for Sustained Intra-Articular Immune Modulation in Adjuvant-Induced Arthritis Rodent Model.Pharmaceutics · 2022Article
- Regioselective synthesis of methyl 5-(Beilstein journal of organic chemistry · 2022Article
- A Facile Approach to Bis(isoxazoles), Promising Ligands of the AMPA Receptor.Molecules (Basel, Switzerland) · 2021Article
- Preclinical Study of Immunological Isoxazole Derivatives as a Potential Support for Melanoma Chemotherapy.International journal of molecular sciences · 2021Article
- New water-soluble isoxazole-linked 1,3,4-oxadiazole derivative with delocalized positive charge.RSC advances · 2021Article
- Synthesis, Physicochemical Characteristics and Plausible Mechanism of Action of an Immunosuppressive Isoxazolo[5,4-e]-1,2,4-Triazepine Derivative (RM33).Pharmaceuticals (Basel, Switzerland) · 2021Article
- Selected βMolecules (Basel, Switzerland) · 2021Review
- Affinity of Antifungal Isoxazolo[3,4-Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, we present reports on the immunoregulatory properties of isoxazole derivatives classified into several categories, such as immunosuppressive, anti-inflammatory, immunoregulatory, and immunostimulatory compounds. The compounds were tested in various models using resident cells from rodents and humans, cell lines, and experimental animal disease models corresponding to human clinical situations. Beneficial features of the described isoxazole derivatives include low toxicity and good bioactivity at low doses. In a majority of studies, the activities of investigated compounds were comparable or even higher than registered reference drugs. Whenever possible, a plausible mechanism of action of the investigated compounds and their potential therapeutic utility were proposed. Among the described compounds, particular attention was paid to the class of immune stimulators with a potential application in chemotherapy patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.